Clinical Trials | September 17, 2025
Enveric clears FDA feedback milestone, prepares IND submission for EB-003
IND application for EB-003 expected in early 2026
IND application for EB-003 expected in early 2026
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Element5’s Agentic AI platform will be integrated with the HCHB EHR
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
The FDA is beginning rulemaking to close the “adequate provision” loophole
CRISPR-based detection enables highly specific molecular recognition
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Subscribe To Our Newsletter & Stay Updated
